Movement Alert|WUXI XDC Rises 4.04% in Regular Trading, Singapore Production Line GMP Release Boosts Global Capacity

Market Focus
Aug 20

On August 20, WUXI XDC rose 4.04% in regular trading, trading at 68.9 HKD/share, with turnover of approximately 97.46 million HKD.

On the news front, the company recently announced that its Singapore-based BCM3 dual-function production line for antibody intermediates and drug substance has successfully completed GMP release, marking a new phase in its global capacity expansion. BCM3 will work in coordination with the Wuxi-based BCM1 and BCM2 lines to achieve a substantial leap in production capacity, while the formulation line DP4 is expected to complete GMP release by end of August.

Additionally, the company is scheduled to hold a board meeting on August 24 to review interim results. Fellow WuXi-platform company WuXi AppTec reported H1 revenue growth of 38.93% year-over-year and net profit growth of 29.43%, while fully raising full-year guidance, continuing to boost sector sentiment. Institutional activity also remains supportive, with Schroders PLC having increased its long position to 5.01% earlier this month.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10